http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102154572-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate | 2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102154572-B1 |
| titleOfInvention | Novel composition for BCG prime booster vaccine comprising Rv3628/Rv0351 |
| abstract | The present invention relates to an antigen comprising at least one or more of Rv0351 and Rv3628; And Toll-like receptor 4 ligand (TLR4 ligand), Toll-like receptor 3 ligand (Toll like receptor 3 ligand, TLR3 ligand) and squalene (adjuvant) containing as an active ingredient. It relates to a pharmaceutical composition for a tuberculosis vaccine. In particular, when the composition provided by the present invention is used as a booster after administration of BCG, it overcomes the short-term defense effect, which is a disadvantage of the BCG, and significantly increases the expression level of multifunctional CD4+ T cells essential for the defense effect of Mycobacterium tuberculosis. It can suppress infection of highly pathogenic Mycobacterium tuberculosis in infants and adults and inhibit the reactivation of chronically latent Mycobacterium tuberculosis. |
| priorityDate | 2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 487.